Final data released overnight show Pfizer’s coronavirus disease 2019 (COVID-19) vaccine is 95% effective; the first at-home COVID-19 test receives a regulatory go-ahead; Amazon launches its first digital drugstore.
Citing that the coronavirus disease 2019 (COVID-19) vaccine it developed with BioNTech is as effective as those for shingles and measles, reports The Wall Street Journal, Pfizer announced overnight that it will seek FDA approval for the vaccine within days. Distribution could then occur by year-end for the vaccine, which final data show is 95% effective among those who developed at least 1 symptom of COVID-19, based on results from the nearly 44,000-person trial. Fatigue and headaches were 2 severe adverse effects reported by the participants, but no serious safety issues were seen, and the vaccine appears well tolerated.
A 30-minute, at-home, rapid test for COVID-19 has received the go-ahead from the FDA, notes The New York Times. Developed by Lucira Health in California, the nasal-swab test, which would cost close to $50 and require a prescription, is the first of several rapid tests approved by the FDA that can be performed entirely at home or a doctor’s office. Doing so eliminates the need to ship samples for analyzing and long wait times for results, by utilizing a battery-powered test cartridge that will light up as “positive” or “negative.” Any patient younger than 14 years will need an adult to run the test.
Based in the United States, Amazon Pharmacy’s new service offerings include accepting most major insurance plans, 40% discounts on brand name drugs, and free 2-day delivery for Prime members, according to CNN Business. There will also be savings benefits for uninsured individuals and those not wanting to invoke their insurance coverage. PillPack, another digital drugstore, was acquired by Amazon back in 2018, and Amazon Pharmacy is an extension of that. Discounts of up to 80% on generic medications will also be offered.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More